<DOC>
	<DOCNO>NCT02780674</DOCNO>
	<brief_summary>To evaluate safety tolerability escalating , single subcutaneous dos MEDI7734 adult subject type I interferon-mediated autoimmune disease .</brief_summary>
	<brief_title>A Phase 1 Study MEDI7734 Type I Interferon-Mediated Autoimmune Diseases</brief_title>
	<detailed_description>MEDI7734 human monoclonal antibody bind cause temporary depletion plasmacytoid dendritic cell ( pDCs ) , type white blood cell . The objective study evaluate safety , drug level , pDC level subject give single injection MEDI7734 placebo . The study conduct subject least one five follow autoimmune disease : dermatomyositis , polymyositis , Sjogren 's syndrome , systemic lupus erythematosus , systemic sclerosis . After screen period , subject randomize 3:1 ratio receive single dose MEDI7734 match placebo , administer subcutaneous ( skin ) injection . After , subject evaluate periodically study site least next 85 day .</detailed_description>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Dermatomyositis</mesh_term>
	<mesh_term>Polymyositis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon Type I</mesh_term>
	<criteria>Key 1 . Age 1865 year old 2 . Diagnoses dematomyositis , polymyositis , Sjogren 's syndrome , systemic lupus erythematosus and/or systemic sclerosis base standard criterion . 3 . Weight 40120kg 4 . Stable disease opinion investigator unlikely change subject 's therapeutic regimen would require subsequent 3 month . Key 1 . History hypersensitivity reaction anaphylaxis previous mAb human immunoglobulin therapy . 2 . Chronic hepatitis B , chronic hepatitis C , HIV infection . 3 . History latent active tuberculosis ( TB ) , positive QuantiFERONÂ®TB Gold test screening . 4 . Herpes zoster infection within 3 month randomization 5 . Any following medication within 6 month Day 1 : cyclophosphamide , leflunomide &gt; 20 mg/day , abatacept . 6 . Receipt mAb within 5 published halflives prior Day 1 . 7 . Receipt rituximab experimental Bcell deplete mAb within 6 month Day 1 . 8 . Receipt rituximab experimental Bcell deplete mAb without return CD19 CD20 count lower limit normal . 9 . Receipt alemtuzumab , bone marrow transplantation , stem cell transplantation , total lymphoid irradiation , Tcell vaccination therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Polymyositis , dermatomyositis , Sjogren 's syndrome , SLE , SSc</keyword>
</DOC>